Management of Chronic Hepatitis B in the HIV-Infected Patient

AIDS Reader

Volumn 14, Issue 3, 2004, Pages 122-129+133+136

  Thio, Chloe L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coinfection; Hepatitis B virus; Hepatitis B, chronic; HIV AIDS

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CLEVUDINE; EMTRICITABINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIRUS DNA;

CHRONIC HEPATITIS; COMBINATION CHEMOTHERAPY; COMORBIDITY; DISEASE SEVERITY; DISEASE TRANSMISSION; DNA DETERMINATION; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIVIDUALIZATION; INFECTION COMPLICATION; LIVER DISEASE; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; REVIEW; SEROCONVERSION; SIDE EFFECT; TREATMENT PLANNING; VACCINATION; VIRUS INFECTION;

ADENINE; ALGORITHMS; ANTIVIRAL AGENTS; CLINICAL TRIALS; DECISION TREES; DRUG THERAPY, COMBINATION; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LAMIVUDINE; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS;

EID: 1542615142     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev. 1999;12:351-366.
2. Levine OS, Vlahov D, Koehler J, et al. Seroepidemiology of hepatitis B virus in a population of injecting drug users-association with drug injection patterns. Am J Epidemiol. 1995;142:331-341.
3. Homann C, Krogsgaard K, Pedersen C, et al. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection. J Acquir Immune Defic Syndr. 1991;4:416-420.
4. Rustgi VK, Hoofnagle JH, Gerin JL, et al. Hepatitis B virus infection in the acquired immunodeficiency syndrome. Ann Intern Med. 1984;101:795-797.
5. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168-174.
6. Gilson RJC, Hawkins AE, Beecham MR, et al. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 1997;11:597-606.
7. Colin JF, Cazals-Hatem D, Loriot MA, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999;29:1306-3610.
8. Thio CL, Seaberg EC, Skolasky RL Jr, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921-1926.
9. Vento S, Di Perri G, Garofano T, et al. Reactivation of hepatitis B in AIDS. Lancet. 1989;2:108-109.
10. Lazizi Y, Grangeot-Keros L, Delfraissy JF, et al. Reappearance of hepatitis B virus in immune patients infected with the human immunodeficiency virus type 1. J Infect Dis. 1988;158:666-667.
11. Waite J, Gilson RJ, Weller IV, et al. Hepatitis B virus reactivation or reinfection associated with HIV-1 infection. AIDS. 1988;2:443-448.
12. Biggar RJ, Goedert JJ, Hoofnagle J. Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV. N Engl J Med. 1987;316:630-631.
13. Yeo W, Chan PKS, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70:553-561.
14. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study. Gastroenterology. 1991;100:182-188.
15. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996;2:1104-1108.
16. Scharschmidt BF, Held MJ, Hollander HH, et al. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med. 1992;117:837-838.
17. Solomon RE, Van Raden M, Kaslow RA, et al. Association of hepatitis B surface antigen and core antibody with acquisition and manifestations of human immunodeficiency virus type 1 HIV-1 infection. Am J Public Health. 1990;80:1475-1478.
18. Ockenga J, Tillmann HL, Trautwein C, et al. Hepatitis B and C in HIV-infected patients: prevalence and prognostic value. J Hepatol. 1997;27:18-24.
19. Saves M, Vandentorren S, Daucourt V, et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS. 1999;13:F115-F121.
20. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
21. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
22. Draelos M, Morgan T, Schifman RB, Sampliner RE. Significance of isolated antibody to hepatitis B core antigen determined by immune response to hepatitis B vaccination. JAMA. 1987;258:1193-1195.
23. McMahon BJ, Parkinson AJ, Helminiak C, et al. Response to hepatitis B vaccine of persons positive for antibody to hepatitis B core antigen. Gastroenterology. 1992;103:590-594.
24. Hofer M, Joner-Jemelka HI, Grob PJ, et al. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis. 1998;17:6-13.
25. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286-290.
26. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2001;34:1225-1241.
27. Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma. J Clin Gastroenterol. 2002;35(5 suppl 2):S86-S91.
28. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology. 2002;36:1408-1415.
29. Fattovich G, Giustina G, Realdi G, et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology. 1997;26:1338-1342.
30. Okoshi S, Igarashi M, Suda T, et al. Remote development of hepatocellular carcinoma in patients with liver cirrhosis type B serologically cured for HBs antigenen-da with long-standing normalization of ALT values. Dig Dis Sci. 2002;47:2002-2006.
31. Higashi Y, Tada S, Miyase S, et al. Correlation of clinical characteristics with detection of hepatitis B virus X gene in liver tissue in HBsAg-negative, and HCV-negative hepatocellular carcinoma patients. Liver. 2002;22:374-379.
32. Keeffe EB, Dieterich D, Han SHB, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol. 2004;2:87-106.
33. Wong DK, Cheung AM, O'Rourke K, et al. Effect of alfa-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med. 1993;119:312-323.
34. Krogsgaard K. The long-term effect of treatment with interferon-alpha 2a in chronic hepatitis B. The Long-Term Follow-up Investigator Group. The European Study Group on Viral Hepatitis (EUROHEP). Executive Team on Anti-Viral Treatment. J Viral Hepat. 1998;5:389-397.
35. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology. 1989;10:761-763.
36. Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990;323:295-301.
37. Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology. 1997;113:1660-1667.
38. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology. 2001;120:1828-1853.
39. Lampertico P, Del Ninno E, Vigano M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology. 2003;37:756-763.
40. Wong DK, Yim C, Naylor CD, et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a prredominantly homosexual male population. Gastroenterology. 1995;108:165-171.
41. McDonald JA, Caruso L, Karayiannis P, et al. Diminished responsiveness of male homosexual chronic hepatitis B virus carriers with HTLV-III antibodies to recombinant alpha-interferon. Hepatology. 1987;7:719-723.
42. DiMartino V, Thevenot T, Boyer N, et al. Serum alanine transaminase level is a good predictor of response to interferon alfa therapy for chronic hepatitis B in human immunodeficiency virus-infected patients. Hepatology. 2000;31:1030-1031.
43. di Martino V, Lunel F, Cadranel JF, et al. Long-term effects of interferon-alpha in five HIV-positive patients with chronic hepatitis B. J Viral Hepat. 1996;3:253-260.
44. Marcellin P, Boyer N, Colin JF, et al. Recombinant alpha, interferon for chronic hepatitis B in anti-HIV positve patients receiving zidovudine. Gut. 1993;34(2 suppl):S106.
45. Zylberberg H, Jiang J, Pialoux G, et al. Alpha-interferon for chronic active hepatitis B in human immunedeficiency virus-infected patients. Gastroenterol Clin Biol. 1996;20:968-971.
46. Visco G, Alba L, Grisetti S, et al. Zidovudine plus interferon alfa-2b treatment in patients with HIV and chronic active viral hepatitis. Gut. 1993;34(2 suppl):S107-S108.
47. Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology. 1995;109:908-916.
48. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
49. Cooksley WG, Piratvisuth T, Lee S-D, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003;10:298-305.
50. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999;341:1256-1263.
51. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med. 1998;339:61-68.
52. Chien RN, Liaw YF, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology. 1999;30:770-774.
53. Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 2000;32(4 pt 1):803-806.
54. Pil HS, Kwang-Hyub H, Hoon AS, et al. Additional lamivudine therapy after HBeAg seroconversion would prolong the durability of response in HBV endemic area. Hepatology. 2001;34:322A. Abstract 600.
55. Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol. 2003;38:818-826.
56. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology. 1999;29:889-896.
57. Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med. 1996;125:705-712.
58. Dore GJ, Cooper DA, Barrett C, et al. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis. 1999;180:607-613.
59. Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology. 2001;33:751-757.
60. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology. 1999;30:1302-1306.
61. Cooley L, Ayres A, Bartholomeusz A, et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS. 2003;17:1649-1657.
62. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000;119:172-180.
63. Lim SG, Wai CT, Rajnakova A, et al. Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut. 2002;51:597-599.
64. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348:808-816.
65. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800-807.
66. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. Lancet. 2001;358:718-723.
67. Xiong S, Yang H, Westland C, et al. Resistance surveillance of HBeAg-chronic hepatitis B patients treated for two years with adefovir dipivoxil. Presented at the 11th International Symposium on Viral Hepatitis and Liver Disease; April 6-10, 2003; Sydney, Australia. Abstract 779.
68. Nunez M, Perez-Olmeda M, Diaz B, et al. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS. 2002;16:2352-2354.
69. Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med. 2003;348:177-178.
70. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS. 2003;17:F7-F10.
71. Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis. 2002;186:1844-1847.
72. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut. 2000;46:562-568.
73. Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol. 2001;35:406-411.
74. Chang TT, Hadziyannis S, Cianciara J, et al. Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine. Hepatology. 2002;36:300A. Abstract 550.
75. Gish R, Leung NW, Wang C, et al. Antiviral activity, safety, and incidence of resistance in chronically infected hepatitis B patients given once daily emtricitabine for 2 years. Hepatology. 2002;36(4 pt 2):372A. Abstract 838.
76. Lai CL, Leung NW, Teo EK, et al. International multicenter trial of LdT (telbivudine) alone and in combination with lamivudine for chronic hepatitis B: an interim analysis. Hepatology. 2002;36(4 pt 2):301A. Abstract 554.
77. Marcellin P, Sacks S, Lau GK, et al. A dose escalating trial evaluating the safety and antiviral activity of clevudine in patients with chronic HBV infection. Presented at Digestive Disease Week; May 18-21, 2003; Orlando, Fla. Abstract 337.
78. Bessesen M, Ives D, Condreay L, et al. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis. 1999;28:1032-1035.
79. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 1998;28:585-589.
80. Neff GW, Bonham A, Tzakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl. 2003;9:239-247.